Business Wire

MI-LINEAGE-LOGISTICS

4.10.2022 20:58:43 CEST | Business Wire | Press release

Share
Lineage Logistics Strengthens Leadership Team, Appoints New Board Member and New Chief Legal Officer

Lineage Logistics, LLC (“Lineage” or the “Company”), the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, today announced the appointment of Lynn Wentworth, a seasoned public board member, to its Board of Directors. Additionally, Lineage also announced the appointment of Natalie Matsler as Chief Legal Officer and Corporate Secretary. In this role, she will oversee Lineage’s global Legal, Safety & Compliance, Food Optimization and Corporate Compliance functions.

Wentworth joins Lineage’s Board of Directors at a pivotal time in the Company’s growth. She brings deep expertise in finance, technology and logistics to Lineage’s board and currently serves on the boards of Graphic Packaging (NYSE: GPK), where she chairs the Compensation & Human Capital Committee, and Benchmark Electronics (NYSE: BHE), where she chairs the Audit Committee. She is the former Chairman of CyrusOne and Cincinnati Bell and chaired the Audit & Finance Committees at both companies before her role as board chair. Before her board service, Wentworth was the Chief Financial Officer and Treasurer of BlueLinx Holdings Inc. (NYSE: BXC), a leading distributor of building products in North America. Prior to joining BlueLinx, she held numerous leadership positions with BellSouth Corporation across tax, strategic planning, investor relations, financial planning, sales and operations and was ultimately appointed CFO – Communications Group.

“As Lineage continues to grow and execute our mission of transforming the food supply chain to eliminate waste and help feed the world, we are thrilled to welcome Lynn to the board,” said Adam Forste, Co-Executive Chairman of Lineage and Co-Founder of Bay Grove. “Given her many years of experience working in areas of finance, technology and logistics, combined with her exceptional board service at a number of industry-leading corporations, we look forward to having Lynn provide a unique and valuable perspective to our board governance and our overall strategy as we continue to fuel Lineage’s global growth.”

“At such a pivotal time in the company’s history, I’m excited to join Lineage’s board of directors and to work with the leadership team as we continue to innovate and grow the global cold chain,” said Wentworth.

As the newest member of Lineage’s Executive Leadership Team, Matsler reports directly to President and CEO Greg Lehmkuhl. Most recently, she served as General Counsel of McCourt Partners, a private investment platform based in Los Angeles, Calif., where she was a member of the executive team and successfully led several projects in real estate development featuring green technology and resilient design. This is her second time working for Lineage, as she originally joined Lineage in 2014 and served in multiple legal leadership roles at the Company, including Senior Vice President and Deputy General Counsel, through April 2021. Before joining Lineage, Matsler held legal roles of increasing responsibility at Latham & Watkins LLP, Downey Savings and Loan Association, F.A. and U.S. Bank National Association. She earned a bachelor’s degree from the University of California at Los Angeles and her J.D. from the University of California at Los Angeles School of Law.

“We are thrilled to welcome Natalie back to the Lineage family,” said Greg Lehmkuhl, President and CEO of Lineage. “With a proven track record of leading, managing and advising significant projects across our global network, Natalie brings extensive experience to Lineage and will play a key role in advancing the company’s strategic initiatives. I am confident she will build upon our already-strong legal, safety and compliance teams and further contribute to Lineage’s global growth.”

“I am honored and grateful for the opportunity to return to Lineage and lead these incredibly talented teams in such a fast-growing, dynamic organization,” said Matsler. “I look forward to supporting Lineage as the company continues its global growth, all while serving Lineage’s purpose of transforming the food supply chain.”

About Lineage Logistics

Lineage Logistics is the world’s largest temperature-controlled industrial REIT and logistics solutions provider. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity, which spans 20 countries across North America, Europe, and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivaled real estate network and the development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was a 2022 U.S. Best Managed Company, No. 3 in the 2022 CNBC Disruptor 50 list, No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020. (www.lineagelogistics.com)

About Bay Grove

Bay Grove is a principal investment firm dedicated to partnering with strong management teams to invest in and build long-term platform investments. Since 2008, Bay Grove has built Lineage Logistics through acquisitions and investments completed in partnership with entrepreneurs, customers and employees. The firm has deep experience in the warehousing and logistics industry and also seeks to make investments in other attractive sectors. Bay Grove is based in San Francisco. (www.bay-grove.com)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221004006010/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye